Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Study Effect of Baicalein Encapsulated/Loaded Chitosan-Nanoparticle on Allergic Asthma Pathology in Mouse Model Publisher



Wang D1 ; Mehrabi Nasab E2 ; Athari SS3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Internal Medicine of Traditional Chinese Medicine, People's Hospital of Yanting County, Sichuan, 621600, China
  2. 2. Cardiologist, Department of Cardiology, School of Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

Source: Saudi Journal of Biological Sciences Published:2021


Abstract

Asthma as chronic airway disease has high prevalence in children and imbalance of Th1/Th2 is a critical mechanism in pathogenesis of the asthma. Baicalein as a cell protective and anti-inflammatory flavonoid may have anti-asthma effect. Therefore, for better using lung, baicalein was used in chitosan-nanoparticle as anti-asthma treatment. Baicalein was loaded and encapsulated in chitosan nanoparticle. The morphology, physical characters (particle size, zeta potential and FT-IR) were analyzed. Drug encapsulation and loading capacity, accumulative release-time were studied. After asthma model producing, the mice were treated with L-B-NP and E-B-NP. At least, MCh challenge test, Cytokines measurement and Lung Histopathology were done. Nanoparticles had average size 285 ± 25 nm with negative charge −2.5 mV. The L-B-NP decreased penh value and E-B-NP decreased inflammation. Both nanoparticles increased IL-12 and decreased IL-5. Also, L-B-NP decreased mucus secretion in bronchi. L-B-NP and E-B-NP control immune-allergo-inflammatory response of asthma. L-B-NP controlled AHR and E-B-NP controlled inflammation that can be used as controlling anti-asthma drug. © 2021 The Author(s)